These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36157597)

  • 1. Label-free hyperspectral imaging and deep-learning prediction of retinal amyloid β-protein and phosphorylated tau.
    Du X; Koronyo Y; Mirzaei N; Yang C; Fuchs DT; Black KL; Koronyo-Hamaoui M; Gao L
    PNAS Nexus; 2022 Sep; 1(4):pgac164. PubMed ID: 36157597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.
    den Haan J; Morrema THJ; Verbraak FD; de Boer JF; Scheltens P; Rozemuller AJ; Bergen AAB; Bouwman FH; Hoozemans JJ
    Acta Neuropathol Commun; 2018 Dec; 6(1):147. PubMed ID: 30593285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
    Huber CM; Yee C; May T; Dhanala A; Mitchell CS
    J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease.
    Davis MR; Robinson E; Koronyo Y; Salobrar-Garcia E; Rentsendorj A; Gaire BP; Mirzaei N; Kayed R; Sadun AA; Ljubimov AV; Schneider LS; Hawes D; Black KL; Fuchs DT; Koronyo-Hamaoui M
    bioRxiv; 2024 Sep; ():. PubMed ID: 39345568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Amyloid and Tau in the Retina: Current Research and Future Directions.
    Tang MY; Blazes MS; Lee CS
    J Neuroophthalmol; 2023 Jun; 43(2):168-179. PubMed ID: 36705970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of CSF pTau measurement by Aβ
    Guo T; Korman D; La Joie R; Shaw LM; Trojanowski JQ; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2020 Aug; 12(1):97. PubMed ID: 32799929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study.
    Klaver AC; Coffey MP; Bennett DA; Loeffler DA
    Transl Neurodegener; 2017; 6():32. PubMed ID: 29204273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular indicators of Alzheimer's: exploring disease in the retina.
    Hart NJ; Koronyo Y; Black KL; Koronyo-Hamaoui M
    Acta Neuropathol; 2016 Dec; 132(6):767-787. PubMed ID: 27645291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and App
    Nuñez-Diaz C; Andersson E; Schultz N; Pocevičiūtė D; Hansson O; ; Nilsson KPR; Wennström M
    Alzheimers Res Ther; 2024 Jan; 16(1):4. PubMed ID: 38167557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
    Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
    ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease.
    Raulin AC; Doss SV; Heckman MG; Craver EC; Li Z; Ikezu TC; Sekiya H; Liu CC; Martens YA; Rosenberg CL; Kuchenbecker LA; DeTure M; Reichard RR; Nguyen AT; Constantopoulos E; Larsen RA; Kounaves EK; Murray ME; Dickson DW; Petersen RC; Bu G; Kanekiyo T
    Acta Neuropathol Commun; 2024 Feb; 12(1):25. PubMed ID: 38336940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.
    Tariciotti L; Casadei M; Honig LS; Teich AF; McKhann Ii GM; Tosto G; Mayeux R
    J Alzheimers Dis; 2018; 65(4):1417-1425. PubMed ID: 30149454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of fluid biomarkers in Alzheimer's Disease.
    Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
    Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.